28-Aug-2026
Novavax announces regulatory approvals for updated COVID shot
Seeking Alpha News (Fri, 28-Aug 9:25 AM ET)
PRNewswire (Fri, 28-Aug 8:30 AM ET)
HHS advisors to discuss boosting funding for autism care
Seeking Alpha News (Thu, 27-Aug 11:02 AM ET)
White House is said to announce drug pricing deals with biotechs
Seeking Alpha News (Wed, 26-Aug 12:40 PM ET)
Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights
PRNewswire (Thu, 6-Aug 8:00 AM ET)
Novavax to Report Second Quarter 2026 Financial Results on August 6, 2026
PRNewswire (Thu, 30-Jul 7:00 AM ET)
Novavax to Participate in 2026 Jefferies Global Healthcare Conference
PRNewswire (Mon, 1-Jun 4:00 PM ET)
Novavax’s Matrix-M Partnerships Expand to Over 30 Therapeutic Targets Amid Revenue Shift
Market Chameleon (Thu, 7-May 4:20 AM ET)
Market Chameleon (Mon, 30-Mar 4:14 AM ET)
Market Chameleon (Thu, 26-Feb 5:35 AM ET)
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
Novavax trades on the NASDAQ stock market under the symbol NVAX.
As of August 28, 2026, NVAX stock price climbed to $9.26 with 3,927,597 million shares trading.
NVAX has a beta of 2.35, meaning it tends to be more sensitive to market movements. NVAX has a correlation of 0.19 to the broad based SPY ETF.
NVAX has a market cap of $1.53 billion. This is considered a Small Cap stock.
Last quarter Novavax reported $57 million in Revenue and -$.32 earnings per share. This beat revenue expectation by $5 million and exceeded earnings estimates by $.05.
In the last 3 years, NVAX traded as high as $23.86 and as low as $3.53.
The top ETF exchange traded funds that NVAX belongs to (by Net Assets): XBI, VTI, IWM, VB, VBK.
NVAX has outperformed the market in the last year with a price return of +22.2% while the SPY ETF gained +19.7%. However, in the short term, NVAX had mixed performance relative to the market. It has underperformed in the last 3 months, returning -10.3% vs +2.2% return in SPY. But in the last 2 weeks, NVAX shares have fared better than the market returning +15.0% compared to SPY -0.9%.
NVAX support price is $8.74 and resistance is $9.36 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NVAX shares will trade within this expected range on the day.